354 related articles for article (PubMed ID: 22563432)
1. Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.
Barbieri M; Di Filippo C; Esposito A; Marfella R; Rizzo MR; D'Amico M; Ferraraccio F; Di Ronza C; Duan SZ; Mortensen RM; Rossi F; Paolisso G
PLoS One; 2012; 7(4):e35999. PubMed ID: 22563432
[TBL] [Abstract][Full Text] [Related]
2. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice.
Duan SZ; Ivashchenko CY; Russell MW; Milstone DS; Mortensen RM
Circ Res; 2005 Aug; 97(4):372-9. PubMed ID: 16051889
[TBL] [Abstract][Full Text] [Related]
3. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
[TBL] [Abstract][Full Text] [Related]
4. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
5. PPAR agonist-induced reduction of Mcp1 in atherosclerotic plaques of obese, insulin-resistant mice depends on adiponectin-induced Irak3 expression.
Hulsmans M; Geeraert B; Arnould T; Tsatsanis C; Holvoet P
PLoS One; 2013; 8(4):e62253. PubMed ID: 23620818
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor-γ in capillary endothelia promotes fatty acid uptake by heart during long-term fasting.
Goto K; Iso T; Hanaoka H; Yamaguchi A; Suga T; Hattori A; Irie Y; Shinagawa Y; Matsui H; Syamsunarno MR; Matsui M; Haque A; Arai M; Kunimoto F; Yokoyama T; Endo K; Gonzalez FJ; Kurabayashi M
J Am Heart Assoc; 2013 Jan; 2(1):e004861. PubMed ID: 23525438
[TBL] [Abstract][Full Text] [Related]
7. LT175 is a novel PPARα/γ ligand with potent insulin-sensitizing effects and reduced adipogenic properties.
Gilardi F; Giudici M; Mitro N; Maschi O; Guerrini U; Rando G; Maggi A; Cermenati G; Laghezza A; Loiodice F; Pochetti G; Lavecchia A; Caruso D; De Fabiani E; Bamberg K; Crestani M
J Biol Chem; 2014 Mar; 289(10):6908-6920. PubMed ID: 24451380
[TBL] [Abstract][Full Text] [Related]
8. Effects of DSP-8658, a novel selective peroxisome proliferator-activated receptors a/γ modulator, on adipogenesis and glucose metabolism in diabetic obese mice.
Goto T; Nakayama R; Yamanaka M; Takata M; Takazawa T; Watanabe K; Maruta K; Nagata R; Nagamine J; Tsuchida A; Kato H
Exp Clin Endocrinol Diabetes; 2015 Sep; 123(8):492-9. PubMed ID: 26011171
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor (PPAR)-gamma positively controls and PPARalpha negatively controls cyclooxygenase-2 expression in rat brain astrocytes through a convergence on PPARbeta/delta via mutual control of PPAR expression levels.
Aleshin S; Grabeklis S; Hanck T; Sergeeva M; Reiser G
Mol Pharmacol; 2009 Aug; 76(2):414-24. PubMed ID: 19483106
[TBL] [Abstract][Full Text] [Related]
10. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
Touyz RM; Schiffrin EL
Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
[TBL] [Abstract][Full Text] [Related]
12. Sex dimorphic actions of rosiglitazone in generalised peroxisome proliferator-activated receptor-gamma (PPAR-gamma)-deficient mice.
Duan SZ; Usher MG; Foley EL; Milstone DS; Brosius FC; Mortensen RM
Diabetologia; 2010 Jul; 53(7):1493-505. PubMed ID: 20401461
[TBL] [Abstract][Full Text] [Related]
13. Differential roles of cardiomyocyte and macrophage peroxisome proliferator-activated receptor gamma in cardiac fibrosis.
Caglayan E; Stauber B; Collins AR; Lyon CJ; Yin F; Liu J; Rosenkranz S; Erdmann E; Peterson LE; Ross RS; Tangirala RK; Hsueh WA
Diabetes; 2008 Sep; 57(9):2470-9. PubMed ID: 18511847
[TBL] [Abstract][Full Text] [Related]
14. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
15. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
[TBL] [Abstract][Full Text] [Related]
16. Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress.
Sekulic-Jablanovic M; Petkovic V; Wright MB; Kucharava K; Huerzeler N; Levano S; Brand Y; Leitmeyer K; Glutz A; Bausch A; Bodmer D
PLoS One; 2017; 12(11):e0188596. PubMed ID: 29182629
[TBL] [Abstract][Full Text] [Related]
17. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.
Hu S; Yao J; Howe AA; Menke BM; Sivitz WI; Spector AA; Norris AW
Mol Endocrinol; 2012 Jun; 26(6):977-88. PubMed ID: 22474127
[TBL] [Abstract][Full Text] [Related]
18. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
Leisewitz AV; Urrutia CR; Martinez GR; Loyola G; Bronfman M
J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
[TBL] [Abstract][Full Text] [Related]
19. Oleanolic acid induces a dual agonist action on PPARγ/α and GLUT4 translocation: A pentacyclic triterpene for dyslipidemia and type 2 diabetes.
Loza-Rodríguez H; Estrada-Soto S; Alarcón-Aguilar FJ; Huang F; Aquino-Jarquín G; Fortis-Barrera Á; Giacoman-Martínez A; Almanza-Pérez JC
Eur J Pharmacol; 2020 Sep; 883():173252. PubMed ID: 32534078
[TBL] [Abstract][Full Text] [Related]
20. The effects of perfluorinated chemicals on adipocyte differentiation in vitro.
Watkins AM; Wood CR; Lin MT; Abbott BD
Mol Cell Endocrinol; 2015 Jan; 400():90-101. PubMed ID: 25448844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
